Revelation Biosciences Management
Management criteria checks 3/4
Revelation Biosciences' CEO is James Rolke, appointed in May 2020, has a tenure of 4.67 years. total yearly compensation is $649.25K, comprised of 73.2% salary and 26.8% bonuses, including company stock and options. directly owns 0.016% of the company’s shares, worth $414.86. The average tenure of the management team and the board of directors is 4.7 years and 4.3 years respectively.
Key information
James Rolke
Chief executive officer
US$649.3k
Total compensation
| CEO salary percentage | 73.2% |
| CEO tenure | 4.7yrs |
| CEO ownership | 0.02% |
| Management average tenure | 4.7yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Revelation Biosciences surges 46% on licensing deal with Vanderbilt University
Oct 06Revelation Biosciences GAAP EPS of -$0.12
Aug 15Revelation Biosciences stock slides 47% on pricing $5M securities offering
Jul 26Revelation Biosciences: Therapeutics And Diagnostics For Respiratory Viral Infections
Mar 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$16m |
| Jun 30 2024 | n/a | n/a | -US$16m |
| Mar 31 2024 | n/a | n/a | -US$9m |
| Dec 31 2023 | US$649k | US$475k | -US$120k |
| Sep 30 2023 | n/a | n/a | US$875k |
| Jun 30 2023 | n/a | n/a | US$2m |
| Mar 31 2023 | n/a | n/a | US$2m |
| Dec 31 2022 | US$480k | US$400k | -US$11m |
| Sep 30 2022 | n/a | n/a | -US$13m |
| Jun 30 2022 | n/a | n/a | -US$15m |
| Mar 31 2022 | n/a | n/a | -US$16m |
| Dec 31 2021 | US$618k | US$400k | -US$12m |
| Sep 30 2021 | n/a | n/a | -US$11m |
| Dec 31 2020 | US$273k | US$167k | -US$4m |
Compensation vs Market: James's total compensation ($USD649.25K) is about average for companies of similar size in the US market ($USD641.95K).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
CEO
James Rolke (55 yo)
4.7yrs
Tenure
US$649,250
Compensation
Mr. James M. Rolke serves as Chief Executive Officer and Director at Revelation Biosciences, Inc. since May 2020. Mr. Rolke has many years of experience in the biotechnology industry, spanning all areas an...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.7yrs | US$649.25k | 0.016% $ 414.9 | |
| CFO & Corporate Secretary | 4.7yrs | US$479.14k | 0.015% $ 404.4 | |
| Vice President of Human Resources & Investor Relations | 5yrs | no data | no data | |
| Senior Director of Clinical Projects | no data | no data | no data |
4.7yrs
Average Tenure
Experienced Management: REVB's management team is considered experienced (4.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.7yrs | US$649.25k | 0.016% $ 414.9 | |
| Independent Chairman | 4.7yrs | US$49.34k | 0.033% $ 858.9 | |
| Independent Director | 1.3yrs | US$15.00k | no data | |
| Independent Director | 4.3yrs | US$79.34k | 0.00096% $ 25.2 | |
| Independent Director | 4.7yrs | US$109.34k | 0.0025% $ 64.9 | |
| Member of Scientific Advisory Board | 1.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.8yrs | no data | no data |
4.3yrs
Average Tenure
59yo
Average Age
Experienced Board: REVB's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 00:06 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Revelation Biosciences, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonathan Aschoff | Roth MKM |
| Bradley Sorensen | Zacks Small-Cap Research |